QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
Not yet recruiting · NCT07009145 · Registry updated 2025-06-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 2 | 2025-06-06 | NCT07009145 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Linyi Tumour Hospital | 2 |
| Qianfoshan Hospital | 88 |
| Qingdao Central Hospital | 10 |
| Shandong Provincial Hospital | 112 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital of Shandong First Medical University | Jinan | China | 9 |